Get the Stockscreener App
9.66
1.43%
-0.14
Pre-market:
9.67
0.010
+0.10%
Biocryst Pharmaceuticals Inc stock is traded at $9.66, with a volume of 10.80M.
It is down -1.43% in the last 24 hours and up +26.94% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$9.80
Open:
$10.13
24h Volume:
10.80M
Relative Volume:
2.12
Market Cap:
$2.42B
Revenue:
$874.84M
Net Income/Loss:
$263.86M
P/E Ratio:
8.0293
EPS:
1.2031
Net Cash Flow:
$327.41M
1W Performance:
+4.89%
1M Performance:
+26.94%
6M Performance:
+24.32%
1Y Performance:
+20.00%
1-Day Range:
$9.42
$10.13
1-Week Range:
$8.91
$10.32
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.66 | 2.42B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Insider Sell: Theresa Heggie Sells 49,933 Shares of BioCryst Pha - GuruFocus
Major Insider Move at BioCryst Shakes Up Investor Buzz - TipRanks
Buybacks Report: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Hereditary Angioedema Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Biocryst Pharmaceuticals Insider Sold Shares Worth $504,823, According to a Recent SEC Filing - marketscreener.com
Option exercise and sale by BioCryst (BCRX) director Theresa Heggie - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpWhat's Next? - MarketBeat
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trading the Move, Not the Narrative: (BCRX) Edition - Stock Traders Daily
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
Portfolio Update: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Market Trends & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Sectors: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 144 BIOCRYST PHARMACEUTICALS INC For: 20 March - Investing.com
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz - Insider Monkey
BCRX Should I Buy - Intellectia AI
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Insider Monkey
BioCryst Takeover Rumors Test Investor Focus On Fundamentals And Optionality - Yahoo Finance
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals: Why This $2B Drugmaker Is Suddenly On Big Pharma’s Radar! - Smartkarma
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares - Investing.com India
BCRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock - MarketBeat
BioCryst (BCRX) CLO sells 150K shares after option exercise - Stock Titan
Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength - Sahm
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its Profitability And Revenue Turnaround - Sahm
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real (NASDAQ:BCRX) - Seeking Alpha
BioCryst (BCRX) Soars 13% on Acquisition Buzz - Insider Monkey
BioCryst Pharmaceuticals Stock Jumps 13.8% - National Today
10 Stocks Worth Watching Right Now: Tencent, Circle, BioCryst and More - Insider Monkey
BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics - Quiver Quantitative
Form 144 resale notice lists 150,000 shares (NASDAQ: BCRX) - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8%Here's What Happened - MarketBeat
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves - StocksToTrade
BioCryst gains amid takeover speculation - MSN
Top Biotech Stocks To Keep An Eye OnMarch 16th - MarketBeat
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition - timothysykes.com
BioCryst Pharmaceuticals (BCRX) Surges 15% Amid Takeover Specula - GuruFocus
BioCryst Stock Surges on Profit Milestone and Upgrades - TipRanks
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Avoro Capital Advisors Trims Stake in BioCryst Pharmaceuticals - National Today
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Whale Trades: Will BioCryst Pharmaceuticals Inc benefit from green energy policiesMarket Activity Recap & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances - MSN
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC - MarketBeat
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):